Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081192 | 0.83 | OPRM1 (0.39) | HRH3GPR119CHIAHTR1ADRD4 | |
| SCHEMBL20012582 | 0.80 | HRH3 (0.36) | HRH3GPR119CHIAHTR1ADRD4 | |
| SCHEMBL18081168 | 0.79 | CHIA (0.36) | HRH3GPR119AVPR2CHIAHTR1A | |
| SCHEMBL20009020 | 0.76 | DRD3 (0.39) | HRH3DRD4HTR2ASLC6A4HTR7 | |
| SCHEMBL20009060 | 0.76 | HRH3 (0.43) | HRH3DRD4 | |
| SCHEMBL20009044 | 0.73 | KDM4E (0.37) | GPR119GRM1 | |
| SCHEMBL17897243 | 0.72 | HRH3 (0.63) | HRH3GPR119F12 | |
| SCHEMBL17897272 | 0.71 | HRH3 (0.47) | HRH3GPR119GRM1F12 | |
| SCHEMBL30046919 | 0.71 | RET (0.52) | HRH3GPR119 | |
| SCHEMBL20009027 | 0.71 | CYP11B2 (0.35) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | HRH3 203/4885GPR119 687/4885AVPR2 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.